Instituto Portugues De Oncologia De Coimbra Francisco Gentil E.P.E.

At Instituto Portugues De Oncologia De Coimbra Francisco Gentil E.P.E., most trials focus on neoplasms, especially advanced cancers where new treatment options are needed. The research is centered on evaluating novel therapies and combination approaches to improve disease control, survival, and treatment response in patients with difficult-to-treat tumors.

• Breast cancer, including hormone receptor-positive, HER2-negative, HER2-positive, and triple-negative disease
• Lung cancer, including non-small cell and small cell lung cancer
• Melanoma and other advanced solid tumors
• Purpose: testing new therapies and comparing them with current standards to improve survival and disease control

The site’s Medical Oncology team is actively involved in studies designed to bring more effective options to people with advanced or metastatic cancer.

A major part of the clinical research at this hospital in Coimbra is dedicated to breast cancer, with studies spanning early and advanced disease. These trials are exploring better ways to treat hormone-driven tumors, HER2-related disease, and aggressive subtypes such as triple-negative breast cancer.

• Advanced breast cancer, including ER-positive, HER2-negative disease
• HER2-positive and triple-negative breast cancer
• Early-stage high-risk breast cancer after surgery
• Purpose: evaluating new combinations and treatment strategies to delay progression and improve outcomes

Several studies also look at treatment sequencing and personalized decision-making, aiming to match patients with the most effective therapy for their tumor type.

Another key research area is respiratory tract disease, with a strong emphasis on non-small cell lung cancer and small cell lung cancer. The trials are focused on advanced, metastatic, and newly diagnosed disease, reflecting a broad effort to improve care across different stages of lung cancer.

• Non-small cell lung cancer, including KRAS G12C-mutated disease
• Small cell lung cancer and locally advanced disease
• Purpose: assessing whether new targeted and immune-based treatments can outperform current options
• Focus: improving progression control and extending survival in hard-to-treat lung cancers

This work highlights the site’s interest in both precision medicine and immunotherapy for thoracic malignancies.

The site is also active in head and neck squamous cell carcinoma research, including recurrent, metastatic, and unresectable disease. These trials are designed to explore better systemic treatments for cancers that are often challenging to manage once they spread or return.

• Recurrent or metastatic head and neck squamous cell carcinoma
• Locally advanced unresectable head and neck cancer
• Purpose: testing immunotherapy-based approaches and new treatment combinations
• Goal: improving survival and disease control after standard local therapies are no longer enough

Research in this area reflects a strong interest in immuno-oncology and in expanding options for patients with limited alternatives.

Clinical trials at Instituto Portugues De Oncologia De Coimbra Francisco Gentil E.P.E. also cover digestive system diseases, especially gastric cancer, gastroesophageal junction adenocarcinoma, and colorectal cancer. These studies are aimed at improving first-line treatment and finding more effective options for advanced disease.

• Gastric cancer and gastroesophageal junction adenocarcinoma
• Colorectal cancer, including KRAS-mutated metastatic disease
• Purpose: evaluating targeted therapies and combination regimens for better tumor control
• Focus: helping patients with advanced digestive tract cancers who need improved treatment choices

The research portfolio in this area suggests a strong commitment to advancing care for both upper and lower gastrointestinal cancers.

Beyond the main tumor types, the site contributes to studies in bladder cancer and to research on personalized diagnostics and treatment decision tools. These projects support a broader effort to tailor therapy more precisely and to improve how clinicians choose the best treatment for each patient.

• High-risk non-muscle-invasive bladder cancer
• Relapsed ovarian cancer and metastatic breast cancer with fluid-related complications
• Purpose: improving treatment selection, predicting response, and comparing outcomes with standard care
• Theme: combining clinical research with more individualized cancer care

These trials add a precision-medicine dimension to the oncology program, complementing the site’s broader work in physiological processes and treatment effectiveness research.